Aptose Biosciences Inc. Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Note 9 - Other Expenses

9 Months Ended

Sep. 30, 2018

Other expenses

Components of research and development expenses:

	Three months ended September 30,				Nine months ended September 30,
	2018		2017		2018		2017
Program costs, excluding salaries	$	2,773	$	1,017	$	7,249	$	2,956
Salaries		502		321		1,448		1,064
License fee, CrystalGenomics (a),(b)		-		-		5,000		-
Stock-based compensation		307		43		826		168
Depreciation and amortization		9		9		26		25
	$	3,591	$	1,390	$	14,549	$	4,213

May 7, 2018,

under the license agreement with CrystalGenomics the Company, the Company paid the option fee of

$2.0

million in cash to CrystalGenomics in order to exercise early the option and gain an exclusive license to develop and commercialize CG-

806

in all territories outside of Korea and China. Future milestone payments are described in note

10.

June 13, 2018,

the Company paid

$3.0

million in cash to CrystalGenomics to gain an exclusive license to develop and commercialize CG-

806

in China. Future milestone payments are described in note

10.

Components of general and administrative expenses:

	Three months ended September 30,				Nine months ended September 30,
	2018		2017		2018		2017

General and administrative excluding salaries	$	853	$	712	$	3,149	$	1,980
Salaries		503		483		1,577		1,784
Stock-based payment financing fees (note 6(a)(iii)		-		-		600		-
Stock-based compensation		644		112		2,869		498
Depreciation and amortization		20		12		38		40
	$	2,020	$	1,319	$	8,233	$	4,302

Components of finance expense:

	Three months ended September 30,				Nine months ended September 30,
	2018		2017		2018		2017
Foreign exchange loss	$	-	$	-	$	20	$	-

Components of finance income:

	Three months ended September 30,				Nine months ended September 30,
	2018		2017		2018		2017
Interest income	$	80	$	21	$	198	$	40
Foreign exchange gain		9		48		-		102
	$	89	$	69	$	198	$	142